Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ITOC 2015 /
Raising the bar in melanoma treatment with immuno-oncology

25th - 27th Mar 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.05.15
Views: 2433

Prof Winald R. Gerritsen - Radboud University Medical Center, Nijmegen, The Netherlands

Prof Winald speaks about our understanding of the immune system’s role in cancer and how it has evolved, leading to the identification of a range of novel therapeutic targets.

Immunotherapies designed to directly harness the patient’s own, highly adaptable, immune system to fight cancer have changed how we treat patients with melanoma.

Data suggest these agents offer the potential for long-term survival in some patients. With further data indicating that combining immunotherapies may improve antitumour activity and potentially clinical outcomes.

See also: 

Immuno-oncology: Changing the landscape of cancer therapy

PD-1 inhibition in lung cancer: Paving the way for a brighter future

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation